Universal Beteiligungs und Servicegesellschaft mbH Has $2.59 Million Stock Position in Henry Schein, Inc. $HSIC

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 28.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,020 shares of the company’s stock after selling 13,204 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Henry Schein were worth $2,589,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in HSIC. Ameriprise Financial Inc. raised its position in Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares in the last quarter. Bank of America Corp DE raised its position in Henry Schein by 204.2% during the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after purchasing an additional 668,182 shares in the last quarter. SG Americas Securities LLC raised its position in Henry Schein by 171.9% during the fourth quarter. SG Americas Securities LLC now owns 820,698 shares of the company’s stock valued at $62,028,000 after purchasing an additional 518,914 shares in the last quarter. Artisan Partners Limited Partnership raised its position in Henry Schein by 5.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock valued at $453,509,000 after purchasing an additional 370,837 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in Henry Schein during the third quarter valued at approximately $15,375,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $74.59 on Friday. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.29. The stock has a market cap of $8.56 billion, a price-to-earnings ratio of 22.81, a P/E/G ratio of 2.18 and a beta of 0.88. The company’s fifty day moving average is $76.59 and its 200 day moving average is $74.68.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Henry Schein’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts forecast that Henry Schein, Inc. will post 5.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HSIC. JPMorgan Chase & Co. boosted their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wells Fargo & Company boosted their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Morgan Stanley reaffirmed an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Finally, Citigroup started coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $87.75.

Insider Buying and Selling

In related news, CEO Stanley M. Bergman sold 43,812 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $81.31, for a total value of $3,562,353.72. Following the sale, the chief executive officer owned 383,803 shares of the company’s stock, valued at $31,207,021.93. The trade was a 10.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Mark E. Mlotek sold 5,925 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the completion of the sale, the executive vice president directly owned 80,554 shares in the company, valued at approximately $6,508,763.20. This represents a 6.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 105,911 shares of company stock valued at $8,574,982 over the last quarter. 0.89% of the stock is currently owned by company insiders.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.